These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 31013158

  • 1. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
    Lee CH, Lee SW, Son SH, Hong CM, Jeong JH, Jeong SY, Ahn BC, Lee J.
    Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
    [Abstract] [Full Text] [Related]

  • 2. SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.
    Deng Y, Zhu G, Ouyang W, Pan L, Feng H, Wu J, Chen P, Wang J, Xian J.
    Endocr Pract; 2019 Sep; 25(9):887-898. PubMed ID: 31170371
    [Abstract] [Full Text] [Related]

  • 3. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
    Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
    [Abstract] [Full Text] [Related]

  • 6. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.
    Kim SK, So Y, Chung HW, Yoo YB, Park KS, Hwang TS, Kim B, Lee WW.
    Cancer Med; 2016 Oct; 5(10):2756-2762. PubMed ID: 27539659
    [Abstract] [Full Text] [Related]

  • 7. Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer.
    Kwon SY, Kim J, Jung SH, Chong A, Song HC, Bom HS, Min JJ.
    Clin Nucl Med; 2016 Jan; 41(1):e32-8. PubMed ID: 26164179
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of preoperative 18F-FDG PET/CT in papillary thyroid cancer patients with a high metastatic lymph node ratio: a multicenter retrospective cohort study.
    Kwon SY, Choi EK, Kong EJ, Chong A, Ha JM, Chun KA, Cho IH, Bom HS, Min JJ, Kim J, Song HC, O JH, Kim SH.
    Nucl Med Commun; 2017 May; 38(5):402-406. PubMed ID: 28306621
    [Abstract] [Full Text] [Related]

  • 9. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters.
    Araz M, Soydal Ç, Özkan E, Akkuş P, Nak D, Küçük NÖ, Kır KM.
    Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
    [Abstract] [Full Text] [Related]

  • 10. Lymph node standardized uptake values at pre-treatment 18F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma.
    Jeong Y, Baek S, Park JW, Joo JH, Kim JS, Lee SW.
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [Abstract] [Full Text] [Related]

  • 11. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.
    Kim BS, Kim SJ, Kim IJ, Pak K, Kim K.
    Thyroid; 2012 Jul; 22(7):725-9. PubMed ID: 22524470
    [Abstract] [Full Text] [Related]

  • 12. Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis.
    Back K, Kim TH, Lee J, Kim JS, Choe JH, Oh YL, Cho A, Kim JH.
    J Pediatr Surg; 2023 Mar; 58(3):568-573. PubMed ID: 35973863
    [Abstract] [Full Text] [Related]

  • 13. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 14. Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.
    Jung JH, Kim CY, Son SH, Kim DH, Jeong SY, Lee SW, Lee J, Ahn BC.
    PLoS One; 2015 Jan; 10(12):e0144152. PubMed ID: 26636824
    [Abstract] [Full Text] [Related]

  • 15. Risk factors of malignant fluorodeoxyglucose-avid lymph node on preablation positron emission tomography in patients with papillary thyroid cancer undergoing radioiodine ablation therapy.
    Cho SG, Kwon SY, Kim J, Cho DH, Na MH, Kang SR, Yoo SW, Song HC.
    Medicine (Baltimore); 2019 Apr; 98(16):e14858. PubMed ID: 31008921
    [Abstract] [Full Text] [Related]

  • 16. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Apr; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 17. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
    Shi L, You Q, Wang J, Wang H, Li S, Tian R, Yao X, Wu W, Zhang L, Wang F, Lin Y, Li S.
    Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
    [Abstract] [Full Text] [Related]

  • 18. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T, Kowalska A, Lesiak J, Młynarczyk J.
    Nucl Med Rev Cent East Eur; 2014 Oct; 17(2):87-93. PubMed ID: 25088108
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
    Rizzo A, Perotti G, Zagaria L, Lanni V, Racca M, Palestini N, Salvatori M.
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C, Onal Y, Sager S, Asa S, Ustabasioglu FE, Alis D, Akman C, Sonmezoglu K.
    Curr Med Imaging Rev; 2019 Jun; 15(10):956-964. PubMed ID: 32008523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.